Neximmune strengthens management team with key appointments

Gaithersburg, md., july 14, 2021 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced that jack a. ragheb, md, phd, has been appointed to the newly created position of senior vice president, translational science, bringing more than 30 years of experience in translational and clinical research in the fields of cell therapy, gene therapy, immunology and virology. in addition, matt schiller has been appointed to head of business development, bringing more than 20 years of business development experience across developmental stage life science companies and large pharma.
NEXI Ratings Summary
NEXI Quant Ranking